scholarly journals Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy

2021 ◽  
Author(s):  
Nan Wang ◽  
Renxuan Huang ◽  
Kunmeng Yang ◽  
Yichun He ◽  
Yufei Gao ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Mitochondrial Dynamics ◽  
Temozolomide Chemotherapy

scholarly journals Advances in Immunotherapy for Glioblastoma Multiforme

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Boyuan Huang ◽  
Hongbo Zhang ◽  
Lijuan Gu ◽  
Bainxin Ye ◽  
Zhihong Jian ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Cancer Vaccines ◽  
Immune Checkpoint Blockade ◽  
First Line ◽  
Specific Cancer ◽  
Personalized Approach ◽  
Poor Outcomes ◽  
Temozolomide Chemotherapy ◽  
Primary Malignant Brain Tumor ◽  
First Line Treatment

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.

scholarly journals The therapeutic potential of curcumin for the treatment of glioblastoma multiforme

2020 ◽  
Vol 7 (1) ◽  
pp. 8-16
Author(s):  
T. I. Kushnir ◽  
N. E. Arnotskaya ◽  
I. A. Kudryavtsev ◽  
V. E. Shevchenko
Keyword(s):  
Cell Cycle ◽  
Glioblastoma Multiforme ◽  
Therapeutic Agent ◽  
Therapeutic Potential ◽  
Chemotherapeutic Agents ◽  
Complementary Treatment ◽  
Adjuvant Temozolomide ◽  
Median Survival Rate ◽  
Temozolomide Chemotherapy ◽  
Primary Malignant Brain Tumor

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

Sign in / Sign up

Export Citation Format

Share Document